Brukinsa (zanubrutinib)
$7,806.78
This medicine requires a prescription. See “Prescription Guide”.
We can only help if the medicine is not available in your country. Learn more.
Brukinsa (zanubrutinib) is a Bruton’s Tyrosine Kinase (BTK) inhibitor indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL), Waldenström’s Macroglobulinemia (WM), relapsed/refractory Marginal Zone Lymphoma (MZL).
Brukinsa (zanubrutinib) was approved by the FDA in November 2019 and by the EMA in November 2021.
Brukinsa (zanubrutinib)
What is Brukinsa (zanubrutinib) for?
Brukinsa (zanubrutinib) is used to treat:
- Mantle Cell Lymphoma (MCL) in adult patients who received previous therapy.
- Waldenström’s Macroglobulinemia (WM).
- Adults patients who undergo one regime based on anti-CD20 for relapsed or refractory Marginal Zone Lymphoma (MZL).
Brukinsa (zanubrutinib) is an inhibitor of Bruton’s Tyrosine Kinase (BTK), which impedes the proliferation of malignant B-cell and lessens tumor growth[1].
Where has Brukinsa (zanubrutinib) been approved?
Brukinsa (zanubrutinib) was approved by the FDA in November 2019[2] and by the EMA in November 2021[3].
References
1. Prescribing Information (FDA): Brukinsa (zanubrutinib) [PDF]
BeiGene, September, 2021
2. (FDA) Accelerate Approval: Brukinsa (zanubrutinib) [PDF]
BeiGene, November, 2019
3. (EMA) Brukinsa (zanubrutinib) medicine summary
EMA, December, 2021
| 1 bottle with 120 capsules of 80 mg | 7,806.78 |
|---|
Be the first to review “Brukinsa (zanubrutinib)”
Related products
Colorectal Cancer
Reviews
There are no reviews yet.